Key result
BDI-FS strongly correlates with BDI-II, providing ~97% sensitivity for depression screening in ESRD patients.
Why the study?
Does the BDI-FS accurately screen for depression compared to the BDI-II in patients with end-stage renal disease on hemodialysis?
Population
162 patients with end-stage renal disease (ESRD) on conventional hemodialysis (CHD)
Comparison
Beck Depression Inventory-Fast Screen (BDI-FS) vs Beck Depression Inventory-II (BDI-II)
Design
Cross-sectional
Authors
Loading...
May support BDI-FS for efficient depression screening in hemodialysis; leaves open prospective validation against clinical diagnosis.
Cross-Sectional (n=162)
Does the BDI-FS accurately screen for depression compared to the BDI-II in patients with end-stage renal disease on hemodialysis?
Effect estimate: Pearson r 0.85
p-value: p=<0.0001
The BDI-FS is a highly sensitive and specific tool for efficient depression screening in patients with end-stage renal disease undergoing hemodialysis.
Neitzer et al. (2012) conducted a cross-sectional in End-stage renal disease (ESRD) (n=162). Beck Depression Inventory-Fast Screen (BDI-FS) vs. Beck Depression Inventory-II (BDI-II) was evaluated on Agreement between BDI-II and BDI-FS scores (Pearson r 0.85, p=<0.0001). The BDI-FS strongly correlated with the BDI-II (Pearson r = 0.85, p < 0.0001) and demonstrated 97.2% sensitivity and 91.8% specificity at a cutoff of ≥4 for depression screening in ESRD patients.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: